BMS at June 2022 oncology and hematology congresses

Driving transformative science to advance the future of cancer care for all  

Intended for U.S. scientific audiences only.

Our data at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Annual Meetings reinforce our commitment to transforming the lives of patients with cancer and blood disorders through science. We look forward to sharing research across immuno-oncology, hematology and cell therapy that underscores our efforts to deliver long-term survival and improved outcomes for patients, providing options earlier in the cancer treatment continuum and introducing new mechanisms and clinical approaches. 

Delivering on the future of cancer care  

Hear from our CEO, Giovanni Caforio, MD, and others about our progress in delivering treatment advances for patients with cancer and blood disorders and how we are working to improve outcomes for all impacted by these diseases.

Our data

Read more about our key data being presented.

Learn more about Bristol Myers Squibb’s data presentations 

Delivering longer-term clinical benefits 

Over the past several decades, our innovative medicines have improved how cancer is treated, making longer-term survival and improved outcomes a possibility for more patients. However, our focus remains on what we have yet to accomplish.

Q&A: The evolution of lung cancer research

Our Vice President and Thoracic Cancers Development Lead Abderrahim Oukessou, MD, and lung cancer expert Adam Schoenfeld, MD, Memorial Sloan Kettering Cancer Center, discuss the transforming lung cancer research landscape, including progress across different lung cancer types, stages and patient groups.

Identifying new ways to help red blood cells mature in myelodysplastic syndromes >

Learn from Sandra Kurtin, PhD, ANP-C, AOCN, University of Arizona Cancer Center, about ongoing research to uncover why red blood cells don’t mature properly in myelodysplastic syndromes and how targeting different stages of their maturation may lead to much-needed new therapeutic options.

The power of dual immunotherapy >

Learn about our pursuit of combination strategies to help determine the best treatment for each patient’s unique cancer.

Intervening earlier to change the course of disease

By researching the use of therapies earlier in the cancer treatment continuum, we aim to reduce the risk of recurrence, with the ultimate goal of helping patients live longer and with improved quality of life.

The quest to stop cancer from coming back: How physicians, researchers and advocates are working towards this goal for patients >

Learn from physicians, advocates and researchers, including our Vice President of Oncology Development, Mark Rutstein, MD, about the unmet medical needs in earlier-stage cancer, and the potential for immunotherapy to disrupt the course of recurrence.

Experts weigh in: Immunotherapy in earlier stages of cancer  >

Immunotherapy research has transformed patient care over the course of the past decade. Explore the potential of moving immunotherapy into earlier stages of cancer as told by experts in the field.

Kald Abdallah, driven by a personal passion, wants to discover ways to treat cancer earlier >

Learn about what inspires Kald Abdallah, MD, PhD, our senior vice president and head of Worldwide Medical Oncology, to devote his career to advancing immunotherapy research in earlier stages of cancer. 

Our pursuit of medical innovation

Science never stops. We are committed to making ongoing advancements in cancer research to bring patients new transformational medicines.

Catching a tumor: Highlighting Bristol Myers Squibb’s commitment to facing the challenge of cancer resistance

Cancer cells are not only stubborn, they are smart. Hear from Lata Jayaraman, head of Oncology Drug Discovery at our Mechanisms of Cancer Resistance Thematic Research Center, as she discusses the challenges of finding solutions to cancer resistance mechanisms.

‘Serial killer’ CAR T cells target and destroy tumor cells in Bristol Myers Squibb lab  >

Watch how CAR T cell therapy can surround and kill a tumor cell and learn about how we are exploring CAR T in designing the next generation of cellular therapies. 

The future of cancer care: Transformative innovation for all  >

Samit Hirawat, MD, executive vice president and chief medical officer of Global Drug Development, shares his perspective on the future of cancer treatment. 

Confronting the complexities of cancer >

Learn about our multi-pronged approach to cancer research across the biological spectrum and a variety of modalities to address critical unmet needs. 

Making scientific breakthroughs accessible and equitable for all

All patients deserve access to quality care and effective treatments. Through our commitment to health equity, we are working to improve outcomes across all populations impacted by cancers and blood disorders.

COLORS training program spreads education of healthcare needs in the LGBTQ+ community

Learn about our dedication to addressing health disparities through our COLORS training program, designed to help oncologists understand the unique challenges and medical needs facing LGBTQ+ patients.

Fulfilling our role in diversifying clinical trials >

Read about the importance of increasing diversity in clinical trials and our dedication to making our trials more racially and ethnically diverse.

Advancing our commitment to health equity >

Adam Lenkowsky, senior vice president and general manager of U.S. Cardiovascular, Immunology and Oncology, addresses the barriers to care that exist for underserved patients. Discover our commitment to improving access.

Patients have a single goal: The best care possible. But too often African American patients with multiple myeloma aren’t getting it >

We take a holistic view toward narrowing the gap in outcomes for African Americans with multiple myeloma because so many factors have contributed to this issue for so long. 

Resources

Our research spans several types of cancer and blood disorders. Learn about some of them below.

Resource hubs

Exploring the tumor microenvironment

Exploring the tumor microenvironment to better understand how cancer and the immune system coexist is a core component of our research and early development strategy.

Cell therapy
resources

Discover how cell therapies are unlocking new potential in cancer research and in some of the most difficult-to-treat blood cancers.

Protein degradation and resources

Learn about the science behind protein degradation and ongoing research that harnesses the power of this natural process.

 

Fact sheets

LAG-3 fact
sheet

Learn about the LAG-3 immune
checkpoint.

Immunotherapy in earlier stages of cancer fact sheet

Explore the potential of immunotherapy in earlier stages of cancer. 

Clinical trials and diversity fact sheet

Learn about the importance of clinical trials and the role of diversity. 

Disease state infographics

 

Download infographic resources on different cancers and disease types.